Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 14 at 2:00 PM EDT

Register Free →
logo
Get CLEATUS

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Therapeutic Agent Characterization and Preclinical Efficacy Studies

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program, managed by the National Institutes of Health and the HEAL initiative, seeks to fund pharmacodynamic, pharmacokinetic, and efficacy studies for therapeutic agents. The goal is to demonstrate that small molecules or biologics possess sufficient biological activity to justify further development as treatments for supported disorders or as non-opioid analgesics with minimal addiction liability. Efficacy testing may be performed using validated in vivo models or New Approach Methodologies. This opportunity is currently listed as a forecast, meaning applications are not being solicited at this time. The notice serves to allow potential applicants to establish collaborations and develop responsive projects ahead of the formal solicitation. Interested parties can contact the program via the provided email for further inquiries.

General Info

NIH IGNITE program supports early translational studies of non-opioid therapeutics’ biological activity.

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUSA
Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health
Office AddressUSA
Contacts
contact@example.gov

Full Description

Show more

The National Institute of Neurological Disorders and Stroke, National Institute of Aging, the NIH Helping to End Addiction Long Term (HEAL) initiative, and other participating ICs seek to support applications to conduct pharmacodynamic, pharmacokinetic, and efficacy studies to demonstrate that the proposed therapeutic agent(s) have sufficient biological activity to warrant further development as therapeutics for disorders or diseases supported by participating ICs or for non-opioid analgesic therapeutics with little or no addiction liability as a part of the NIH HEAL initiative. Therapeutic agents include small molecules or biologics. Efficacy testing can be conducted in validated in vivo models and/or validated New Approach Methodologies (NAMs) as appropriate.

Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories
Solicitation # 75N98026R00175SB
The National Institutes of Health is issuing a small business sources sought notice to identify qualified vendors capable of providing biobanking, laboratory analytics, and informatics services. The primary objective is to support the NIDA Center for Genetic Studies and the NIH Brain Development Cohorts Biobank, specifically aiding the ABCD and HBCD studies. The scope of work includes the secure storage and management of at least 3.5 million biospecimens, comprehensive data curation, advanced laboratory analytics such as high-throughput sequencing and CRISPR/Cas9 gene editing, and the development of a biorepository web portal with secure cyberinfrastructure. This notice is not a solicitation for proposals but a market research effort to determine if enough capable small businesses exist under NAICS code 541714 to justify a set-aside. Interested small businesses must submit a capability statement detailing their experience, personnel qualifications, and facility capabilities to the designated contracting specialists by October 20, 2026. The government is seeking evidence of technical expertise in GLP and CLIA-certified environments, as well as the ability to maintain FISMA-compliant security documentation for informatics systems.
National Institutes Of Health Nida

POSTED

3 days ago

DEADLINE

in 20 days
View Details
NAICS: 541714
New
Federal
Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories
Solicitation # 75N98026R00175
The National Institutes of Health is issuing a Sources Sought Notice to identify qualified business sources capable of providing biobanking, laboratory analytics, and informatics services. This initiative supports the NIDA Center for Genetic Studies and the NIH Brain Development Cohorts Biobank, specifically aiding the ABCD and HBCD studies. The government is seeking capability statements to determine the availability of technically proficient vendors and to evaluate potential small business set-aside opportunities. The required scope of work involves the secure management and storage of at least 3.5 million biospecimens, comprehensive data curation, and advanced laboratory analytics including high-throughput genotyping and CRISPR/Cas9 gene editing. Additionally, the contractor must provide informatics support, such as developing biorepository web portals and maintaining secure cyberinfrastructure compliant with FISMA and NIH requirements. Interested parties must submit their capability statements, including details on experience, personnel, and facilities, to the designated contract specialists by October 20, 2026.
National Institutes Of Health Nida

POSTED

3 days ago

DEADLINE

in 20 days
View Details
NAICS: 541714
New
Federal
ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening
Solicitation # ARPA-H-SOL-26-165
The Advanced Research Projects Agency for Health (ARPA-H) is seeking proposals under solicitation ARPA-H-SOL-26-165 for the Comprehensive Organ System Modeling in Outer Space (COSMOS) initiative. This program aims to determine if microgravity in Low Earth Orbit (LEO) accelerates tissue aging across brain, cardiac, uterine, and kidney tissues compared to terrestrial rates. If the Tissue Aging Rate in Space (TARIS) is found to significantly exceed the Tissue Aging Rate on Earth (TAROE), the initiative intends to establish a high-throughput, autonomous drug screening platform in LEO to make biomedical research and development more cost-effective and faster than Earth-based methods. The project is structured into two sequential phases: a 27-month Phase I focused on establishing and validating microphysiological systems (MPS) to quantify aging rates, and a 15-month Phase II dedicated to developing age-related pathology models for pro-regenerative drug testing. Key requirements include the use of MPS or organoids for at least 75 percent of experimental samples, the creation of LEO twin experiments, and the establishment of a contractual partnership with at least one Fortune 100 biopharmaceutical company. The program schedule spans FY27 through FY30 and includes two planned space launches in months 39 and 41. Awards will be granted via multiple Other Transaction (OT) Agreements to the most advantageous proposers, including universities, non-profits, and businesses. Evaluation is based primarily on the innovation and feasibility of the technical approach, the potential to transform biomedicine, and the team's expertise in managing costs and schedules. Proposers must adhere to strict administrative requirements, including the BIOSECURE Act, NIH Genomic Data Sharing policies, and specific research security and cybersecurity disclosures. Full proposals are due by October 7, 2026.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

6 days ago

DEADLINE

in 7 days
View Details
NAICS: 541714
New
Federal
ARPA-H Emerging Health Innovators (EHI) Initiative
Solicitation # ARPA-H-SOL-26-150
The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, is a mentorship program designed to identify and engage early-career investigators for cutting-edge biomedical, health, and community-engaged research. Eligible principal investigators must be within eight years of completing their first terminal degree. The program focuses on 16 specific topic areas and utilizes a two-step submission process, beginning with an anonymized solution summary due October 30, 2026, followed by full proposals due February 10, 2027. Awards are issued as Other Transaction (OT) agreements with a tentative start date of June 30, 2027. Each award has a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a two-year base period capped at 700,000 dollars and an optional third year capped at 350,000 dollars. Funding is structured around a fixed-price milestone payment schedule, with 12 total quarterly milestones and payments processed through the Payment Management Services (PMS) system. Performance is monitored via monthly one-hour virtual reviews with the ARPA-H program team. Evaluation is based on technical merit, innovativeness, feasibility, and alignment with the ARPA-H mission, with a strong emphasis on risk mitigation and the potential to impact national health research.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

6 days ago

DEADLINE

in 4 months
View Details
NAICS: 541714
New
Grant
Imaging Biomarker Research & AnalysisThis subcontract focuses on the development and testing of imaging-based biomarkers designed to identify pancreatic cancer and its precursor lesions. Working in support of prime contractors on NIH and NCI research projects, the scope of work involves utilizing advanced imaging modalities including MRI, CT, PET, and endoscopic ultrasound to characterize lesions and establish specialized protocols for identifying high-risk patients. Because the work involves human subject research, all activities must be conducted under appropriate IRB approval. The primary deliverables for this engagement consist of finalized imaging biomarker protocols and comprehensive analyzed imaging datasets. This opportunity is categorized under NAICS code 541714 and is associated with the National Institutes of Health within the Department of Health and Human Services. Interested parties must note the response deadline of November 5, 2029, to participate in this research and analysis initiative.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in about 3 years
View Details
NAICS: 541714
New
Grant
NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
Solicitation # PAR-28-072
The National Institutes of Health National Eye Institute is offering a bi-phasic, milestone-driven award through the Translational Research Program for Therapeutics (PAR-28-072) to accelerate the transition of laboratory research into biological, pharmaceutical, or medical device therapies for visual system diseases. The program is structured into two phases: an R61 phase of up to two years focusing on preliminary data and lead optimization, and an R33 phase of up to four years dedicated to final preclinical development and the filing of an Investigational New Drug or Investigational Device Exemption application with the FDA. The total combined duration of both phases cannot exceed five years. Transition to the R33 phase is contingent upon the administrative assessment of satisfactory completion of SMART milestones, which must include required pre-submission feedback from the FDA. Budgetary limits for direct costs are generally capped at 500,000 dollars per year for the R61 phase and 1,000,000 dollars per year for the R33 phase. Applicants must provide a Target Product Profile, a Gantt chart, and an Intellectual Property Strategy, while ensuring compliance with Good Manufacturing Practices and Good Laboratory Practice standards. Evaluation is based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Eligible applicants, including small businesses and other for-profit organizations, must maintain active registrations in the System for Award Management and eRA Commons, and all principal investigators must have a linked ORCID ID. Awardees are also required to implement cybersecurity incident reporting procedures and an incident response plan in accordance with HHS guidelines.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in about 3 years
View Details
NAICS: 541714
New
Grant
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Solicitation # PAR-28-056
The National Institutes of Health, through the National Cancer Institute, is soliciting applications for Research Units (RUs) to join the Pancreatic Cancer Detection Consortium (PCDC). This initiative focuses on the early detection of pancreatic ductal adenocarcinoma (PDAC) and the characterization of precursor lesions to identify high-risk patients. Multi-disciplinary teams will conduct research to identify and test molecular and imaging biomarkers in bodily fluids, develop markers for pancreatic cysts, create screening approaches for high-risk populations, and utilize machine learning for biomarker discovery and validation. Additionally, RUs are required to collect longitudinal biospecimens for a biorepository and engage in collaborative data and resource sharing within the consortium. The award has a five-year project period with a budget limit of 600,000 dollars in direct costs per year. For years two through five, recipients must set aside 100,000 dollars in direct costs annually for trans-PCDC collaborative studies, subject to Steering Committee approval. Key personnel requirements include a minimum commitment of 1.2 person-months per year for the Contact PD/PI and any other PD/PIs. Eligible applicants include for-profit organizations and small businesses, though foreign entities are excluded. Applications are evaluated via the NIH peer review system based on significance, innovation, feasibility, and the expertise of the investigators and their environment. Compliance requirements include maintaining active SAM and eRA Commons registrations and adhering to strict cybersecurity incident reporting timelines of 48 hours. Projects involving clinical trials must be registered on ClinicalTrials.gov and receive NIH approval prior to initiation. Required application materials include SF424 forms, a Resource Sharing Plan, a Data Management and Sharing Plan, and letters of institutional commitment. Awardees must also budget for travel to attend two Steering Committee meetings annually.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in about 3 years
View Details
NAICS: 541714
New
Grant
NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
Solicitation # PAR-28-072
The National Eye Institute's Translational Research Program (TRP) aims to accelerate the transition of laboratory research into clinical therapeutics for visual system diseases. This program supports the development of pharmaceutical, biological, medical device, or combination therapies through a bi-phasic, milestone-driven award structure. All projects begin with an R61 phase for up to two years to support research with significant preliminary data. Successful projects may transition to an R33 phase for up to four years, focusing on final preclinical development, filing IND/IDE packages with the FDA, and designing future clinical trials. The combined duration of both phases cannot exceed five years. A critical requirement of this program is the establishment of SMART milestones for both phases, which must be specific, measurable, achievable, relevant, and time-bound. Applicants are encouraged to provide contingency plans to address potential delays in meeting these goals. The ultimate objective of the R33 phase is for recipients to either obtain an IND/IDE application or transition the product into clinical practice within the performance period. This solicitation, identified as PAR-28-072, is issued by the National Institutes of Health.
National Eye Institute

POSTED

6 days ago

DEADLINE

in about 3 years
View Details
NAICS: 541714
New
Grant
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Solicitation # PAR-28-056
The National Cancer Institute is soliciting applications for Research Units as part of the Pancreatic Cancer Detection Consortium to advance the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions. These multi-disciplinary teams will focus on developing and testing molecular and imaging biomarkers to identify high-risk patients and those with lesions likely to progress to cancer. Key research activities include the use of machine learning for biomarker discovery, conducting validation studies, and collecting longitudinal biospecimens for a centralized biorepository. Under solicitation PAR-28-056, the selected Research Units are required to engage in collaborative efforts, sharing data and biospecimens across the consortium. The initiative aligns with the NCI's scientific framework for pancreatic cancer by prioritizing the identification of patients who could benefit from early intervention based on genetic factors, family history, or existing precursor lesions. Applications for this federal opportunity are due by November 6, 2029.
National Cancer Institute

POSTED

6 days ago

DEADLINE

in about 3 years
View Details
NAICS: 541714
New
Federal
UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)
Solicitation # ARPA-H-SOL-26-162
The Advanced Research Projects Agency for Health (ARPA-H) has issued Innovative Solutions Opening (ISO) ARPA-H-SOL-26-162 for the UNifying Imaging with QUantum Entanglement (UNIQUE) program. This 18-month, two-phase initiative seeks to develop a new biomedical imaging paradigm by integrating anatomical, functional, and molecular data with quantum-derived observables and entangled 511 keV photon pairs. The scope is divided into two technical areas: TA1, which focuses on the physical systems required to generate and measure quantum observables in biomedical settings, and TA2, which focuses on the computational foundation, including AI-driven reconstruction and multimodal data fusion. ARPA-H anticipates awarding multiple Other Transaction (OT) Agreements to eligible entities, including universities, non-profit organizations, and businesses. For-profit organizations that exceed the NAICS 541714 SBA size standard of 1,000 employees are required to provide a meaningful cost share. The application process follows a two-stage submission cycle, with Solution Summaries due by late October 2026 and Full Proposals due by December 15, 2026, with a final response deadline of December 16, 2026. Full proposals must consist of three volumes covering technical and management plans, cost proposals, and administrative requirements. Evaluation is based on the innovation and feasibility of the technical approach, the expertise of the personnel, the potential to transform biomedicine, and cost reasonableness. Key requirements include compliance with HHS regulations on human stem cells, adherence to cybersecurity standards, and restrictions on gain-of-function research and funding for foreign entities in countries of concern. Awardees will be expected to provide monthly status reports and participate in semi-annual in-person PI review meetings.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

7 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Federal
HUBBLE DRAFT Program Announcement (PA)
Solicitation # DARPA-PA-26-10_DRAFT
The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office is issuing a presolicitation notice for the HUBBLE program, which aims to develop an in-silico capability for mapping all protein-protein interactions. The goal is to create a comprehensive human interactome hypercatalog, demonstrating its utility by identifying novel diagnostic and therapeutic targets for conditions such as traumatic brain injury. The program is structured in two phases, with Phase 1 lasting 12 months and Phase 2 lasting 18 months. Key deliverables include the development of PPI fingerprinting capabilities, the capture of a minimal interactome for mild traumatic brain injury, and the generation of a massive PPI hypercatalog benchmarked against DARPA-provided experimental datasets. Awards will be issued as Other Transactions for Research under 10 U.S.C. 4021, meaning they are not subject to the Federal Acquisition Regulation or the Defense Federal Acquisition Regulations Supplement. Eligible applicants include large and small businesses, universities, research institutions, and nontraditional defense contractors. Proposers must be registered in the System for Award Management and maintain CMMC Level 1 compliance. Evaluation is based on technical comprehension, technical ability, and the reasonableness of the cost rough order of magnitude. Submissions must be made via DARPA's Broad Agency Announcement Tool, and all abstracts must remain unclassified.
Defense Advanced Research Projects Agcy

POSTED

7 days ago

DEADLINE

in 1 day
View Details
NAICS: 541714
New
Federal
UNifying Imaging with QUantum Entanglement (UNIQUE) Proposers' Day
Solicitation # ARPA-H-SN-26-162
The Advanced Research Projects Agency for Health (ARPA-H), through its Health Science Futures Office, has issued Special Notice ARPA-H-SN-26-162 to announce the UNifying Imaging with QUantum Entanglement (UNIQUE) program. This initiative aims to establish a new biomedical imaging paradigm by utilizing quantum-derived observables, specifically entangled or quantum-correlated 511 keV photon pairs, to reveal disease biology that is currently invisible to existing imaging technologies. The program is divided into two technical areas: an Imaging Core focused on physical systems and quantum-aware detectors, and a second area focused on AI-driven reconstruction and fusion methods to integrate anatomical, functional, molecular, and quantum-derived information. To support this effort, a hybrid Proposers Day is scheduled for October 16, 2026, at 8:30am ET, held at the Executive Conference Center in Arlington, Virginia. This event is designed to provide technical details, promote teaming, and alert the scientific community to an upcoming Innovative Solutions Opening (ISO) that was scheduled for release by September 18, 2026. Interested parties are encouraged to use the provided Lightning Talk Template to showcase their capabilities and teaming goals. While this notice provides program goals and technical direction, it is issued for information and planning purposes and does not constitute a formal solicitation for proposals. The primary point of contact for the program is Program Manager Wilfred Ngwa.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

7 days ago

DEADLINE

in 13 days
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

New
Grant
Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)The National Institutes of Health is forecasting a Notice of Funding Opportunity to solicit applications for early to definitive clinical trials. This initiative seeks proposals testing a wide range of interventions, including drugs, devices, biologics, procedures, and behavioral or social interventions, provided they align with the research missions of the participating NIH Institutes, Centers, and Offices. The funding will utilize a bi-phasic, milestone-driven R61/R33 activity code with a maximum project period of seven years. The R61 phase focuses on planning activities, while the R33 phase supports the actual clinical trial. Although applications are not currently being accepted, this notice serves as an advance alert for investigators with expertise in trial design, implementation, and stakeholder engagement to begin developing collaborations and projects.

POSTED

2 days ago

DEADLINE

N/A
View Details
NAICS: 541715
New
Grant
Continuation of the Exceptional Longevity Data Management and Coordinating Center (EL DMCC) (U24 Clinical Trial Not Allowed)The National Institute on Aging intends to issue a single U24 cooperative agreement award to support the continued operation and expansion of the Exceptional Longevity Data Management and Coordinating Center. Serving as the central hub for human longevity translational research, the center integrates deeply phenotyped cohorts and multi-omics datasets to enable cross-cohort analyses and collaborative research. Key responsibilities include data harmonization, the implementation of common data standards, and the management of the ELITE Portal, which provides the research community with secure access to analytical tools and cloud-based computational workspaces. The upcoming funding opportunity will require the Coordinating Center to expand its capabilities in artificial intelligence, machine learning, and the integration of diverse datasets across different species. Future objectives include the development of curated target knowledgebases for therapeutic targets, the enhancement of portal interoperability according to FAIR data principles, and the strengthening of community engagement through specialized training and workshops. This notice serves as a forecast to allow potential applicants to establish collaborations before the official solicitation is released.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Grant
Immune Drivers of Autoimmune DiseaseThe National Institute of Allergy and Infectious Diseases seeks to support the Immune Drivers of Autoimmune Disease network to investigate the triggers and early mechanisms of autoimmunity in humans. The primary goal is to develop tools for risk prediction and staging, identify pre-clinical immune mechanisms, and utilize artificial intelligence and big data to prevent autoimmune diseases. This initiative emphasizes the creation of preclinical cohorts and the use of remote recruitment and sampling to advance medical research. The network will be managed by a Coordinating Center responsible for data harmonization, sample sharing, and the administration of an Infrastructure Opportunity Fund for collaborative research projects. This forecast, issued by the National Institutes of Health under the Department of Health and Human Services, establishes a framework for shared infrastructure and steering committee oversight to identify common pathways and prevention opportunities.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 513130
New
Grant
NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)The National Institutes of Health, through the Department of Health and Human Services, is soliciting applications for the NLM Grants for Scholarly Works in Biomedicine and Health program. This initiative provides funding for the creation of book-length manuscripts and other integrative scholarly works, such as critical reviews and analytical syntheses, designed to benefit U.S. health professionals, scientists, and public health practitioners. The primary goal is to organize and disseminate biomedical and health-related knowledge to improve research, education, and clinical practice. This opportunity is listed as a forecast with a posted date of September 24, 2026. It specifically prohibits the use of clinical trials. Interested parties can contact the NLM Extramural Programs office for further information regarding the application process and program requirements.
Book Publishers

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Grant
Partnerships for Advancing Development of Diagnostics for Infectious DiseasesThe National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is seeking to establish partnerships between academic or small business investigators and industrial partners to advance the translational development of diagnostic tests for infectious diseases. This initiative focuses on moving diagnostics that have already demonstrated proof-of-concept through the commercialization process by aligning researchers with experienced industry partners to de-risk development and ensure products are fit for purpose. The program will be supported by a science advisory board and NIAID oversight, incorporating annual meetings and workshops to facilitate collaboration and knowledge exchange. This effort is authorized under the Public Health Service Act and federal regulations to ensure that promising diagnostic technologies are successfully translated into tools for treating and preventing infectious diseases.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541715
New
Grant
LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE)The National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting the LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE) program. This initiative aims to bridge the gap between traditional clinical trial findings and real-world application by supporting collaborations on effectiveness trials, pragmatic trials, and hybrid effectiveness-implementation studies. The program focuses on the prevention and treatment of HIV, including associated coinfections and comorbidities, across all age groups and various points of care. The goal of the program is to advance cross-cutting research in epidemiology, implementation science, and clinical, behavioral, and social sciences. This effort aligns with the broader NIH mission to implement research advances in HIV/AIDS. The opportunity is authorized under the Public Health Service Act and relevant federal regulations, with administrative oversight provided by the Division of AIDS Epidemiology Branch.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541715
New
Grant
Collaborative Centers in Children’s Environmental Health Research and Translation (P2C Clinical Trial Optional)The National Institutes of Health, under the Department of Health and Human Services, is seeking applications to establish a national network of Children's Environmental Health Research Translation Centers. These centers are designed to protect and improve children's health by developing scientific questions and public health interventions focused on translational research. A primary objective is to move evidence-informed biomedical findings into practical application for the wider community while mentoring a new generation of investigators in the field. Beyond research and translation, the program will function as a national resource to coordinate responses to emerging environmental exposures that impact children. The initiative emphasizes the creation of actionable strategies to prevent harm and ensure a healthy future for children through collaborative efforts within the environmental health community.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Grant
The Role of the Innate Immune System in the Pathogenesis of Type 1 DiabetesThe National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting a grant opportunity to investigate the role of the innate immune system in the initiation of Type 1 Diabetes. Funded by the Special Statutory Funding Program for Type 1 Diabetes Research, this initiative seeks to identify genetic and environmental causes of the disease by examining how innate immune components interact with beta cells and pancreatic tissues. The program emphasizes the use of new approach methodologies to determine the timing and impact of environmental triggers that activate these immune pathways. The primary objective is to improve the early identification of high-risk individuals and develop future prevention and therapeutic strategies. This effort is conducted under the authority of the Public Health Service Act and relevant federal regulations. Interested parties can contact the RISP-T1D point of contact for further information regarding this forecast.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)The National Institute of Neurological Disorders and Stroke (NINDS) is seeking to support scientific research using data from intermediate-size patient population expanded access protocols for Amyotrophic Lateral Sclerosis (ALS). To be eligible, protocols must provide access to an investigational drug or biological product for individuals with ALS and generate data that supports research into the prevention, diagnosis, mitigation, treatment, or cure of the disease. Research goals may include analyzing the effects of products on biomarkers, target engagement, safety and outcome information such as survival and hospitalization, or general patient experience data. This opportunity is currently listed as a forecast by the National Institutes of Health under the Department of Health and Human Services, and applications are not being solicited at this time. The notice serves as a preliminary announcement to allow potential applicants sufficient time to develop responsive projects. Interested parties can contact the ALS Program for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

8 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Research to Improve Rigor, Replicability, and Reproducibility in Biomedical and Behavioral SciencesThe National Institute of Neurological Disorders and Stroke, in collaboration with other NIH entities, is forecasting support for research projects aimed at enhancing biomedical and behavioral rigor, replicability, and reproducibility. Key areas of interest include assessing the scientific impact of these improvements, creating frameworks for selecting high-value replication studies, and measuring the robustness and generalizability of research findings to drive scientific innovation. This notice serves as a forecast to allow potential applicants to establish collaborations and develop responsive projects, as formal applications are not currently being solicited. Interested parties can contact the NINDS Office of Research Quality for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)The National Institutes of Health, through the National Institute of Mental Health, is issuing a forecast for a Notice of Funding Opportunity titled Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs). This initiative aims to establish a research network to evaluate the clinical effectiveness, safety, and durability of rapid-acting treatments such as ketamine, esketamine, and psilocybin for individuals with serious mental illnesses. The primary objective is to generate actionable real-world evidence to determine how these interventions can be safely and sustainably integrated into routine clinical practice across diverse patient populations and healthcare settings. By addressing current gaps in knowledge regarding implementation and long-term benefits, the project seeks to inform future healthcare delivery strategies for emerging psychotropic treatments.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

15 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Emerging Global Leader Award (K43)The Emerging Global Leader Award (K43), issued by the National Institutes of Health under the Department of Health and Human Services, provides salary and research support to junior faculty and research scientists based at academic or research institutions in Low- and Middle-Income Countries. The program focuses on biomedical, behavioral, and clinical research that leverages unique opportunities in these regions to create generalizable knowledge benefiting both U.S. and international populations. Recipients must engage in intensive mentored research and career development guided by senior researchers from both the U.S. and their respective home countries. By leveraging existing NIH research investments, the initiative aims to develop global research leaders who can mentor future investigators and strengthen international research networks.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

15 days ago

DEADLINE

N/A
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS